From theheart.org on Medscape

Coverage from the

European Society of Cardiology (ESC) Congress 2020

August 29 - September 01, 2020; Virtual

August 29 - September 01, 2020 Virtual

Meeting Highlights At A Glance

ESC 2020 Highlights: Drugs Old and New Top trials from the virtual ESC 2020 featured old drugs such as aspirin and colchicine as well as the new SGLT2 inhibitors.
ESC 2020 Highlights: Treatment Strategies & the Virtual Experience The first randomized trial on stopping ACE inhibitors and ARBs in patients with COVID-19, and a comparison of rhythm vs rate control in AF are among the strategies tested in trials presented at ESC 2020.

Conference News

ESC 2020 Study Questions Routine Long-term Beta-Blocker Post MI
Medscape Medical News, September 24, 2020
ESC 2020 New ESC Guidelines on Adult Congenital Heart Disease
Medscape Medical News, September 24, 2020
ESC 2020 Novel Calculator Predicts Cancer Risk in Patients With CVD
Medscape Medical News, September 17, 2020
ESC 2020 European Sports Cardiology Guidelines Break New Ground
Medscape Medical News, September 17, 2020
ESC 2020 ISCHEMIA Revisited: Some May Benefit From Invasive Strategy
Medscape Medical News, September 15, 2020
ESC 2020 'Low-Risk' Valvular AF in Some May Warrant Oral Anticoagulation
Medscape Medical News, September 11, 2020
ESC 2020 Sudden Death Not So Sudden? Half Contacted GP in Days Prior
Medscape Medical News, September 9, 2020
ESC 2020 Elderly May Not Reap Post-MI Ticagrelor Advantage vs Clopidogrel
Medscape Medical News, September 9, 2020
ESC 2020 The Earlier the Better for Colchicine Post-MI: COLCOT
Medscape Medical News, September 8, 2020
ESC 2020 Early Evolocumab Quickly Lowers LDL After Primary PCI
Medscape Medical News, September 4, 2020
ESC 2020 Final EVAPORATE Results for Vascepa Raise Eyebrows
Medscape Medical News, September 4, 2020
ESC 2020 Saliva Troponin Test for MI Has 'Huge Potential,' But Still Early
Medscape Medical News, September 3, 2020
ESC 2020 Extra Ticagrelor Benefit When PAD Adds to CAD, Diabetes: THEMIS
Medscape Medical News, September 3, 2020
ESC 2020 Raised Troponin Linked to Worse COVID-19 Outcomes
Medscape Medical News, September 3, 2020
ESC 2020 REALITY Trial Supports Restrictive Transfusion in Anemic MI
Medscape Medical News, September 2, 2020
ESC 2020 IMPACT-AFib: Single Mailing Fails to Budge Anticoagulant Uptake
Medscape Medical News, September 2, 2020
ESC 2020 Mini-Dose Edoxaban May Safely Cut AF Stroke Risk in Very Elderly
Medscape Medical News, September 1, 2020

ESC 2020 ESC Guideline on Non ST-Elevation ACS
Medscape Medical News, September 1, 2020
ESC 2020 HOME-PE Trial Clarifies Which PE Patients to Treat at Home
Medscape Medical News, September 1, 2020
ESC 2020 First Randomized Trial Reassures on ACEIs, ARBs in COVID-19
Medscape Medical News, September 1, 2020
ESC 2020 Gut Bacteria Linked to Cardiovascular, Other Health Conditions
Medscape Medical News, September 1, 2020
ESC 2020 LoDoCo2: Added Steam for Colchicine as Secondary Prevention
Medscape Medical News, August 31, 2020
ESC 2020 Antihypertensive Treatment Beneficial at Normal BP Levels
Medscape Medical News, August 31, 2020
ESC 2020 Victory in HFpEF Again Evades ARNI Despite Hopeful Signals
Medscape Medical News, August 31, 2020
ESC 2020 RATE-AF Trial Boosts Digoxin for Rate Control in Permanent AF
Medscape Medical News, August 30, 2020
ESC 2020 DAPA-CKD: SGLT2 Inhibitor Benefits CKD Without Diabetes
Medscape Medical News, August 30, 2020
ESC 2020 ATPCI: Trimetazidine Fizzles for Post-PCI Angina
Medscape Medical News, August 30, 2020
ESC 2020 Evolocumab Safe and Effective in Pediatric FH
Medscape Medical News, August 30, 2020
ESC 2020 New ESC/EACTS Guideline on Atrial Fibrillation
Medscape Medical News, August 30, 2020
ESC 2020 Aspirin Alone Preferred Antithrombotic Strategy After TAVI
Medscape Medical News, August 30, 2020
ESC 2020 EAST-AFNET 4: Early Rhythm Control in AF Gains New Life
Medscape Medical News, August 29, 2020
ESC 2020 EXPLORER Hints at Potential New Drug Option in Obstructive HCM
Medscape Medical News, August 29, 2020
ESC 2020 Empagliflozin's HFrEF Benefit Solidifies Class Effects
Medscape Medical News, August 29, 2020
ESC 2020 ESC 2020 Looks to Make Its Mark in 'New Era' of Virtual Meetings
Medscape Medical News, August 25, 2020

© WebMD, LLC

Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.

Perspectives

Surgery Still Best Option in Obstructive HCM
Patrick O. Myers, MD; Eduard Quintana, MD, PhD
Arrhythmia and Atrial Fibrillation Highlights From ESC 2020
Rachel Lampert, MD
Heart Failure Highlights From ESC 2020
Akshay S. Desai, MD, MPH
DAPA-CKD: SGLT2 Inhibitors 'The Beta-Blockers for the Kidneys'
Jennie J. Lin, MD, MSc; Leslie S. Gewin, MD
Seven Quick Thoughts on the New European AF Guidelines Teaser
John Mandrola, MD
ESC 2020: Top 3 Studies
Prof Mamas Mamas
ESC: DAPA-HF & SGLT2 Inhibitors a Year on
Prof John McMurray
EAST-AFNET 4 Favors Rhythm Control, but It's Complicated
John Mandrola, MD
SGLT2 Inhibitors in HFrEF: Putting EMPEROR-Reduced in Context
Ileana L. Piña, MD, MPH; Milton Packer, MD
ESC: Guideline Changes Expected After Blood Pressure Study
Prof Kazem Rahimi
Digoxin Stuns in RATE-AF Trial
John Mandrola, MD
Mandrola Previews the Virtual ESC 2020
John Mandrola, MD

Popular News from ESC 2019

PARAGON-HF: Sacubitril/Valsartan Frustrates in Preserved-EF HF Hopes were the trial would provide something new: solid clinical trial backing for an HFpEF drug therapy. It didn't, but some say it supports consideration of the drug in at least one HFpEF subgroup.
Medscape Medical News, Sep 01, 2019
Dapagliflozin: New HF Therapy, Even Sans Diabetes Significant reductions in heart failure events and mortality associated with the diabetes drug in the randomized trial point to a new era in the treatment of heart failure, experts say.
Medscape Medical News, Sep 01, 2019
COMPLETE: Better Outcome With PCI in Nonculprit Lesions After STEMI New data show intervention in nonculprit lesions after STEMI in patients with multivessel disease reduced CV death, recurrent MI, and ischemia-driven revascularization vs a culprit-lesion-only strategy.
Medscape Medical News, Sep 01, 2019

Previous Coverage